Spreafico A, Hansen AR, Abdul Razak AR, et al. The future of clinical Trial Design in Oncology. Cancer Discov. 2021;11(4):822–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kurzrock R, Lin CC, Wu TC, et al. Moving beyond 3 + 3: the future of clinical Trial Design. Am Soc Clin Oncol Educ Book. 2021;41:e133–44.

Article  PubMed  Google Scholar 

Verweij J, Hendriks HR, Zwierzina H, et al. Innovation in oncology clinical trial design. Cancer Treat Rev. 2019;74:15–20.

Article  CAS  PubMed  Google Scholar 

Araujo D, Greystoke A, Bates S, et al. Oncology phase I trial design and conduct: time for a change– MDICT guidelines 2022. Ann Oncol. 2023;34(1):48–60.

Article  CAS  PubMed  Google Scholar 

Li A, Bergan RC. Clinical trial design: past, present, and future in the context of big data and precision medicine. Cancer. 2020;126(22):4838–46.

Article  PubMed  Google Scholar 

Mukai Y, Ueno H. Establishment and implementation of Cancer genomic medicine in Japan. Cancer Sci. 2021;112(3):970–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adashek JJ, LoRusso PM, Hong DS, et al. Phase I trials as valid therapeutic options for patients with cancer. Nat Rev Clin Oncol. 2019;16(12):773–8.

Article  PubMed  PubMed Central  Google Scholar 

Rokuda M, Matsumaru N, Tsukamoto K. Identification of drug characteristics for implementing Multiregional clinical trials including Japan. Clin Ther. 2018;40(2):284–95.

Article  PubMed  Google Scholar 

Corbaux P, El-Madani M, Tod M, et al. Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies. Eur J Cancer. 2019;120:40–6.

Article  CAS  PubMed  Google Scholar 

Mackley MP, Fernandez NR, Fletcher B, et al. Revisiting risk and benefit in early oncology trials in the era of Precision Medicine: a systematic review and Meta-analysis of phase I trials of targeted single-Agent Anticancer therapies. JCO Precis Oncol. 2021;5:17–26.

Article  PubMed  Google Scholar 

Chihara D, Lin R, Flowers CR, et al. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022;400(10351):512–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haslam A, Olivier T, Tuia J, et al. Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers. BMC Cancer. 2023;23(1):46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chihara D, Huang EP, Finnigan SR, et al. Trends in Grade 5 toxicity and response in phase I trials in hematologic malignancy: 20-Year experience from the Cancer therapy evaluation program at the National Cancer Institute. J Clin Oncol. 2022;40(17):1949–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka M, Idei M, Sakaguchi H, et al. Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan. Br J Clin Pharmacol. 2021;87(8):3279–91.

Article  PubMed  Google Scholar 

Noguchi A, Hanaoka H, Uyama Y. Potential future Drug Development lag in Japan based on an analysis of Multiregional clinical trials in the US, Europe, and East Asia. Ther Innov Regul Sci. 2022;56(3):523–9.

Article  PubMed  Google Scholar 

Nakajima K, Dagher R, Strawn L, et al. The relationship between Development Start lag and approval lag in Oncology Drug Development in Japan. Ther Innov Regul Sci. 2015;49(6):911–9.

Article  PubMed  Google Scholar 

Ushijima S, Matsumaru N, Tsukamoto K. Evaluation of drug lags in development initiation, New Drug application and approval between Japan and the USA and the impact of local Versus multi-regional clinical trials. Pharmaceut Med. 2021;35(4):253–60.

PubMed  Google Scholar 

Maeda H, Kurokawa T. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan? Int J Clin Oncol. 2015;20(6):1072–80.

Article  PubMed  Google Scholar 

Maki A, Narukawa M. Exploratory Analysis of Drug Lag in New Oncology drugs between Japan and the US. Ther Innov Regul Sci. 2023;57(4):671–7.

Article  PubMed  Google Scholar 

Nakayama H, Matsumaru N, Tsukamoto K. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States. Invest New Drugs. 2019;37(5):1086–93.

Article  CAS  PubMed  Google Scholar 

Yamashita K, Kaneko M, Narukawa M. A significant anticancer drug approval lag between Japan and the United States still exists for minor cancers. Clin Pharmacol Ther. 2018;105(1):153–60.

Article  PubMed  Google Scholar 

Yamashita K, Kaneko M, Narukawa M. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer. Eur J Clin Pharmacol. 2019;75(9):1193–200.

Article  PubMed  Google Scholar 

Katanoda K, Ito Y, Sobue T. International comparison of trends in cancer mortality: Japan has fallen behind in screening-related cancers. Jpn J Clin Oncol. 2021;51(11):1680–6.

Article  PubMed  PubMed Central  Google Scholar 

Teramae F, Makino T, Lim Y, et al. International Strategy for sustainable growth in multinational Pharmaceutical companies. Sustainability. 2020;12(3):867.

Article  Google Scholar 

Teramae F, Makino T, Lim Y, et al. Impact of Research and Development Strategy on sustainable growth in multinational Pharmaceutical companies. Sustainability. 2020;12(13):5358.

Article  Google Scholar 

Shimizu T. Future perspectives of required multiple infrastructures for achieving sustainable implementation of global first-in-human phase 1 trials in Japan. Ann Oncol. 2022;33(SUPPLEMENT 6):S437.

Article  Google Scholar 

Kohno T, Kato M, Kohsaka S, et al. C-CAT: the National Datacenter for Cancer genomic medicine in Japan. Cancer Discov. 2022;12(11):2509–15.

Article  PubMed  PubMed Central  Google Scholar 

Fukuhara S, Oshikawa-Kumade Y, Kogure Y, et al. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Sci. 2022;113(8):2763–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamada O, Chiu SW, Takata M, et al. Clinical trial monitoring effectiveness: remote risk-based monitoring versus on-site monitoring with 100% source data verification. Clin Trials. 2021;18(2):158–67.

Article  PubMed  Google Scholar 

Huang YJ, Chao WY, Wang CC, et al. Orphan drug development: the impact of regulatory and reimbursement frameworks. Drug Discov Today. 2022;27(6):1724–32.

Article  CAS  PubMed  Google Scholar